Accueil › Cancer de l'ovaire › Floride
Essais cliniques pour Cancer de l'ovaire dans Floride
81 études pour Cancer de l'ovaire recherchent des participants dans Floride.
Villes dans Floride
- Miami23 études
- Orlando22 études
- Tampa21 études
- Jacksonville16 études
- Sarasota16 études
- West Palm Beach11 études
- Miami Beach10 études
- Cape Coral7 études
- St. Petersburg6 études
- Gainesville6 études
- Hollywood4 études
- Plantation4 études
- Deltona4 études
- Fort Lauderdale4 études
- Kendall3 études
- Deerfield Beach3 études
Texte officiel de l'étude (anglais)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- et 6 autres
Recrutement en coursPhase 2
Tous âges · Tous sexes · Mis à jour le 2 oct. 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
- Advent Health, Orlando
- Florida Cancer Specialists South, Port Charlotte
Recrutement en coursPhase 1/2
Âges de 12 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT04585750A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- AdventHealth Cancer Institute, Orlando
Recrutement en coursPhase 1
Âges de 19 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06586957A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06172478Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Tampa
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 1 oct. 2026 · NCT07851025The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Mayo Clinic in Florida, Jacksonville
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT07285044First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Florida Cancer Specialists, Sarasota
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT06799065A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Jacksonville
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0241 - Florida Cancer Specialist - North, Altamonte Springs
- Site 0173 - Mount Sinai Medical Center, Miami Beach
- Site 0308 - Advent Health, Orlando
- et 1 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Femmes · Mis à jour le 29 sept. 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Jupiter Medical Center /ID# 276616, Jupiter
- Mount Sinai Medical Center /ID# 274868, Miami Beach
Recrutement en coursPhase 2
Âges de 18 ans et plus · Femmes · Mis à jour le 29 sept. 2026 · NCT06890338Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Mayo Clinic, Jacksonville
- Genoma Research, Inc., Miami
- Orlando Health, Orlando
- et 1 autres
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Femmes · Mis à jour le 29 sept. 2026 · NCT05051722Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Sarasota
- Avenzo Therapeutics Recruiting Site, Tampa
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 28 sept. 2026 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Coral Springs
- Research Site, St. Petersburg
- Research Site, West Palm Beach
Recrutement en coursÉtude observationnelle
Âges de 18 à 130 · Tous sexes · Mis à jour le 25 sept. 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Jacksonville, Jacksonville
- Moffitt Cancer Center, Tampa
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT04981119Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Florida Cancer Specialists, Sarasota
- Moffitt Cancer Center and Research Institute, Tampa
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- University of Florida College of Medicine /ID# 278348, Gainesville
- Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623, Orlando
- Florida Cancer Specialists - North /ID# 278626, St. Petersburg
- et 1 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Femmes · Mis à jour le 22 sept. 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Broward Health Medical Center, Fort Lauderdale
- Florida Cancer Specialist- South, Fort Myers
- Baptist MD Anderson Cancer Center, Jacksonville
- et 5 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Moffitt, Tampa
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07213791Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sylvester Comprehensive Cancer Center, Miami
- Sara Cannon Research Institute Lake Nona, Orlando
- Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 21 sept. 2026 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Florida Cancer Specialists - Lake Nona, Orlando
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 17 sept. 2026 · NCT07109726Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
- Moffitt Cancer Center, Tampa
Recrutement en coursPhase 1
Âges de 18 ans et plus · Femmes · Mis à jour le 17 sept. 2026 · NCT05316129A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Mount Sinai Cancer Center ( Site 0029), Miami Beach
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 17 sept. 2026 · NCT07318558Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
- Moffitt Cancer Center, Tampa
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 16 sept. 2026 · NCT07487168Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Advent Health, Orlando
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 15 sept. 2026 · NCT06915025A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Florida Cancer Specialists & Research Institute, Fort Myers
- Sylvester Comprehensive Cancer Center, Miami
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- et 1 autres
Recrutement en coursPhase 2
Âges de 18 à 99 · Femmes · Mis à jour le 15 sept. 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Brcr Global, Miramar
- Sarasota Memorial Health Care System, Sarasota
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 15 sept. 2026 · NCT07214779Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- Cleveland Clinic Foundation - Florida, Weston
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 14 sept. 2026 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Mayo Clinic Jacksonville, Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- Advent Health Cancer Institute, Orlando
- et 1 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Femmes · Mis à jour le 14 sept. 2026 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Memorial Healthcare System, Hollywood
- The Oncology Institute of Hope & Innovation, Lakeland
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 14 sept. 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Miami, Miami
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 10 sept. 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Mt. Sinai Comprehensive Cancer Center, Miami
- Sarasota Memorial Health Care System, Sarasota
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 9 sept. 2026 · NCT07225270Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Recrutement en coursPhase 1
Âges de 18 ans et plus · Femmes · Mis à jour le 3 sept. 2026 · NCT07755436A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0078), Miami Beach
- Sarasota Memorial Hospital ( Site 0075), Sarasota
- Florida Cancer Specialists East ( Site 7000), West Palm Beach
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 3 sept. 2026 · NCT06824467A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Florida Cancer Specialists, Orlando
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 27 août 2026 · NCT07186842Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- AdventHealth Cancer Institute, Orlando
- Sarasota Memorial Healthcare System, Sarasota
- Women's Cancer Associates with Women's Care Florida, St. Petersburg
Recrutement en coursPhase 3
Âges de 18 ans et plus · Femmes · Mis à jour le 26 août 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Moffitt Cancer Center, Tampa
Recrutement en coursPhase 1
Âges de 15 ans et plus · Tous sexes · Mis à jour le 25 août 2026 · NCT06276491Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- UF Health Cancer Institute - Gainesville, Gainesville
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 19 août 2026 · NCT07001748A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- SCRI - Florida Cancer Specialists, Sarasota
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 18 août 2026 · NCT07470853A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
- Florida Cancer Specialists - Bradenton Cancer Center, Bradenton
- Morton Plant Hospital, Clearwater
- et 25 autres
Recrutement en cours
Âges de 35 à 50 · Femmes · Mis à jour le 7 août 2026 · NCT04251052Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.